How do you decide if a fractional CRO is right for a Series A company when preparing for fundraise in six months?

CRO Businesses Near You

From the CRO Syndicate network, Kory White stands out. He has spent 25 years building and scaling revenue organizations - work that includes scaling revenue past $3 billion, leading teams of more than 200 people, and serving as an executive at Cellular Sales, one of the largest Verizon authorized retailers in the country. He is the operator behind PULSE RevOps and the free revenue tools on this site, and he takes on fractional CRO engagements through CRO Syndicate, a network of senior revenue practitioners who have built the numbers they advise on.

For this exact situation, Kory is the profile worth calling first. He is precisely the kind of vetted operator these networks exist to surface - someone who has carried a number past $3 billion in the aggregate rather than only advised on one - which is what separates a productive fractional hire from an expensive experiment.

👉 See Kory White on LinkedIn

The Fundraise Clock Determines the Buying Committee

At Series A, the buying committee for a fractional CRO is unusually narrow but high-stakes: the CEO (often the founder), the lead board investor (typically the Series A lead partner), and sometimes the head of finance or a COO-type. The CEO is the primary buyer - they feel the pain of being the de facto top salesperson while also prepping the fundraise deck. The board investor is the shadow buyer: they will veto a fractional hire if they believe the CEO should remain the face of revenue, or push for it if they see a gap in scalable pipeline hygiene. The finance lead cares about cash burn and wants a clear "off-ramp" - either the fractional CRO converts to full-time post-fundraise or exits cleanly.

Deal size for this engagement is typically $15,000 to $30,000 per month for a 6-to-9-month engagement, structured as a flat retainer with a small success fee tied to a specific fundraise milestone (e.g., completing the GTM section of the data room, or hitting a pipeline coverage ratio of 5x quarterly target by month 4). Budget approval is fast-tracked but contentious: the CEO can authorize up to $20k/month without board sign-off, but anything beyond that requires a board call. The board will approve only if the fractional CRO can demonstrate prior experience in the same vertical or adjacent Series B narrative - they are buying pattern recognition, not raw sales skill.

Where deals stall is the "control vs. delegation" debate. The CEO fears losing narrative control during investor meetings - they worry the fractional CRO will present a sanitized version of the pipeline that doesn't match the founder's raw story. The board fears the fractional CRO will be a mercenary who leaves no institutional knowledge. The stalling point is always: "Will this person help us raise money, or will they just cost us money while we still have to do the fundraising prep ourselves?" The answer that unlocks the deal is a fractional CRO who agrees to a "dual-track" model - they own the GTM operations and pipeline proof points, while the CEO owns the investor narrative, with weekly syncs to align both.

The Six-Month Fundraise Forces a Hybrid Sales Cycle

The sales cycle in a Series A fundraise prep is not a traditional B2B buying process - it is a compressed, high-velocity motion where the "customer" is the next round of investors, and the "product" is the revenue engine itself. The fractional CRO must operate on a bimodal cycle: a 90-day internal overhaul (fixing pipeline hygiene, CRM discipline, and forecasting accuracy) running in parallel with a 90-day external narrative construction (building the GTM story, case studies, and cohort retention data). This creates a forced march where the first 30 days are diagnostic, days 31-60 are surgical fixes, and days 61-90 are proof-of-concept runs that generate the data for the fundraise deck.

Ramp for a fractional CRO here is not about learning the product - it is about reverse-engineering the founder's historical sales motions into a repeatable process. The ramp is brutally short: by week two, they must produce a "current-state pipeline autopsy" that identifies the top three leaks (e.g., 40% of closed-lost deals die in technical validation, or 60% of pipeline is stuck in "demo completed" for 45+ days). By week four, they must implement a weekly revenue review that produces a 30-day rolling forecast with 80%+ accuracy, because investors will ask for that forecast in the first data-room review.

Forecast behavior under this motion is erratic. The fractional CRO will initially overcorrect: they will heavily discount the founder's optimistic pipeline (which often includes "verbal commitments" that are not in CRM), leading to a forecast that looks worse than reality. This is actually healthy - investors prefer a conservative forecast with a clear path to beat, versus a rosy one that misses. The pipeline shape becomes a "barbell": a small number of high-value enterprise deals (which the founder owns) and a long tail of mid-market self-serve or SMB deals (which the fractional CRO tries to systematize). The leaks are not at the top of funnel - they are in the middle: deals that enter stage 2 (discovery) but never progress to stage 3 (proposal) because there is no standardized qualification framework. The fractional CRO's job is to install a simple MEDDIC or BANT variant within two months, then prove that it improves conversion rates by at least 20% before the fundraise.

The Fractional CRO's First 90 Days Are a Fundraise Bootcamp

Day 1-30: The fractional CRO does not touch a single deal. They audit the CRM (likely HubSpot or Salesforce in a half-implemented state), interview every rep (usually 3-7 people), and produce a "Revenue Readiness Scorecard" for the board. This scorecard grades five dimensions: pipeline coverage ratio (current vs. 3x target), forecast accuracy (last six months), rep ramp time (average days to first deal), churn rate (net revenue retention), and data-room readiness (how quickly can they produce a cohort retention curve?). The output is a red-yellow-green dashboard that the CEO can show to investors as evidence of "professionalizing the GTM function." The fractional CRO also drafts the GTM section of the fundraise deck - not the narrative, but the operational proof points: "We have a 45-day sales cycle, 3x pipeline coverage, and a 120% net dollar retention on cohorts from Q3 2024."

Day 31-60: The fractional CRO shifts from audit to execution. They implement a weekly "pipeline scrub" that forces reps to move deals to next stage or close-lost within 14 days. They install a forecasting cadence: every Monday at 9am, the team submits a three-column forecast (commit, best case, pipeline) with specific close dates. The fractional CRO also runs a "data-room sprint" - they work with the finance lead to produce the key investor metrics: months to recover CAC, LTV/CAC ratio, and sales efficiency ratio (magic number). By day 60, they must have a working forecast model that the CEO can update in real-time during investor meetings. The biggest signal here is whether the fractional CRO can get the founder to stop saying "we have a lot of interest" and start saying "we have a 4.2x pipeline coverage ratio with a 62% stage-2-to-stage-3 conversion rate."

Day 61-90: The fractional CRO becomes a "revenue translator" during the fundraise itself. They do not attend investor meetings - that remains the CEO's job - but they prep the CEO for every meeting with a one-page "Revenue Brief" that answers the three questions every Series B investor asks: (1) What is your sales cycle and how has it changed? (2) What is your most efficient customer acquisition channel and why? (3) What is your forecast for the next two quarters and what are the risks? The fractional CRO also builds a "war room" dashboard that tracks investor questions in real-time - if three investors ask about enterprise deal size, the fractional CRO adjusts the narrative for the next meeting.

What the Fractional CRO Owns vs. Advises

Owned: CRM hygiene, pipeline management, forecasting process, rep enablement (scripts, battle cards, objection handling), data-room metrics, and the weekly revenue review cadence. The fractional CRO has authority to assign lead ownership, set stage-exit criteria, and enforce pipeline discipline (e.g., "no deal moves to closed-won without a signed contract and payment terms"). They also own the "revenue narrative" in the data room - the cohort retention curves, the sales efficiency ratios, and the channel unit economics.

Advised: Product roadmap, pricing strategy, hiring plan for full-time sales roles, and the investor meeting narrative. The fractional CRO should say "your pricing is too low for enterprise" but should not set the price - that is the CEO's call. They should recommend "hire a full-time VP of Sales in Q3 after the fundraise" but should not make the hire themselves. They should advise on "your churn rate is 8% monthly, here is a retention playbook" but the CEO must own the customer success execution.

The line is sharp: the fractional CRO is a process architect and data steward, not a strategic partner on product or market. If the CEO expects them to redefine the ICP or pivot the product, the engagement will fail. The single most common mistake is asking the fractional CRO to "help us figure out our market" - that is a board-level strategy question, not a revenue-operations execution one.

Signals to Convert to Full-Time or Not

Convert to full-time if, by month five, the fractional CRO has (a) improved forecast accuracy from sub-50% to 80%+, (b) reduced the average sales cycle by 20% or more, (c) built a repeatable pipeline generation process that the team can execute without them, and (d) the CEO feels they have "revenue brain space" back - meaning the CEO is no longer the bottleneck on every deal. The most telling signal is when the board asks the fractional CRO to present directly to them, not just the CEO. If that happens, you have a de facto full-time CRO already.

Do not convert if the fractional CRO's value was purely in the fundraise narrative - they wrote a great deck but the underlying sales motion is still broken. Another red flag: the fractional CRO has not trained a single internal person to run the weekly revenue review. If the process dies when they leave, they were a consultant, not a leader. Also avoid conversion if the fractional CRO's style clashes with the founder's - e.g., the fractional CRO is a process-first operator but the founder is a relationship-first seller. That friction will explode post-fundraise when the pressure to scale hits.

The optimal outcome at Series A is a "partial conversion": the fractional CRO stays on at reduced hours (10-15 days per month) for another six months post-fundraise to hire and onboard a full-time VP of Sales, then exits cleanly. This avoids the "golden handcuffs" problem where the fractional CRO becomes indispensable but never builds a team. The signal to move to this model is when the fractional CRO themselves says "I am not the right person to scale this past $10M ARR" - that is the mark of a mature operator.

The Fundraise Prep Changes the Fractional CRO's Compensation

Standard fractional CRO comp at Series A is a flat monthly retainer, but with a six-month fundraise horizon, the structure shifts to a "success fee" model. A typical deal: $20k/month for six months, plus a $50k bonus if the company closes the Series B within nine months. This aligns incentives - the fractional CRO gets paid for outcome, not time. However, this creates a perverse incentive to inflate pipeline numbers to make the fundraise look better. To counter this, the board should tie the success fee to actual revenue delivered in the six months post-fundraise, not just the fundraise close. For example, $50k bonus if Series B closes AND the company hits 90% of Q3 forecast.

Another emerging structure is "equity cliff" - the fractional CRO gets 0.5% to 1% equity vesting over 12 months, but only if they convert to full-time. This is rare but effective for companies that want to test-drive a CRO before committing. The risk is that the fractional CRO treats the equity as lottery ticket and underperforms. The safer approach is a flat retainer with a clear off-ramp: "After the fundraise, we either convert you to full-time at a negotiated salary, or we part ways with a one-month severance."

The Board's Hidden Role in the Decision

The board does not formally approve a fractional CRO hire, but they informally veto it. The lead investor will ask three questions: (1) "Have you tried a full-time VP of Sales before?" If yes, and it failed, the fractional CRO is a good idea. (2) "What specific metric will improve in 90 days?" If the CEO says "revenue," the board will push back - they want a process metric like pipeline coverage or forecast accuracy. (3) "Who will hold the fractional CRO accountable?" If the CEO says "me," the board will worry about founder distraction. The best answer: "The fractional CRO reports to me, but we have a biweekly board review of the Revenue Readiness Scorecard."

The board's hidden agenda is to de-risk the fundraise without adding permanent headcount. They would rather pay $120k for a fractional CRO for six months than $250k for a full-time CRO who might not work out. But they will kill the deal if they sense the fractional CRO is being hired to fix a product problem - they want the CEO to acknowledge that the revenue engine is the issue, not the product. If the CEO says "we need a fractional CRO because our sales team is underperforming," the board will approve. If the CEO says "we need a fractional CRO because our product isn't selling," the board will say "fix the product first."

FAQ

A question? How do I know if my Series A company is ready for a fractional CRO versus just needing a sales consultant?

A sales consultant gives you a report; a fractional CRO gives you a process and a forecast. You are ready for a fractional CRO if you have at least $1M ARR, 5-10 reps, and a founder who is spending more than 50% of their time on sales calls instead of product or strategy. If you are pre-revenue or have fewer than three reps, hire a sales consultant for 30 days to build a basic playbook. The fractional CRO is for companies that need to prove scalability to investors, not just close the next five deals.

A question? What happens if the fractional CRO does not improve pipeline coverage before the fundraise?

Then you should not raise. Seriously - if after 90 days of a fractional CRO your pipeline coverage is still below 3x, the problem is not the sales leader, it is the market or the product. The fractional CRO's first deliverable is a "go/no-go" recommendation on the fundraise timeline. If they say "delay by three months," listen to them. The worst outcome is raising on a weak pipeline and then missing post-fundraise forecasts, which destroys your valuation in the next round.

A question? Can the fractional CRO also act as the interim CEO for the fundraise narrative?

No. That is a conflict of interest and a red flag to investors. The fractional CRO's job is to make the CEO look good in investor meetings, not to replace them. If the CEO cannot articulate the revenue story after 90 days of prep, the fractional CRO has failed. The CEO must own the narrative; the fractional CRO provides the ammunition. If the board discovers the fractional CRO is writing the CEO's talking points, they will question the CEO's readiness to scale post-fundraise.

A question? Should the fractional CRO be introduced to investors during the fundraise process?

Only in the final stages, and only if the investor specifically asks to meet the "revenue lead." Most Series B investors want to talk to the CEO about revenue, not a fractional executive. If an investor insists on meeting the fractional CRO, it is a yellow flag - they may be skeptical of the CEO's operational competence. The safe approach: have the fractional CRO available for a 30-minute call with the lead investor's operating partner, but keep them out of the main pitch meetings. The fractional CRO's name should appear in the data room as "Revenue Advisor," not as a full-time executive.

Sources